PT815235E - Vacinas para peste - Google Patents

Vacinas para peste

Info

Publication number
PT815235E
PT815235E PT96905956T PT96905956T PT815235E PT 815235 E PT815235 E PT 815235E PT 96905956 T PT96905956 T PT 96905956T PT 96905956 T PT96905956 T PT 96905956T PT 815235 E PT815235 E PT 815235E
Authority
PT
Portugal
Prior art keywords
pct
antigen
pestis
whole
vaccine
Prior art date
Application number
PT96905956T
Other languages
English (en)
Inventor
Richard William Titball
Ethel Diane Williamson
Sophie Emma Clare Leary
Petra Claire Farquhar Oyston
Alice Marie Bennett
Original Assignee
Secr Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27267623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT815235(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9505059.7A external-priority patent/GB9505059D0/en
Priority claimed from GBGB9518946.0A external-priority patent/GB9518946D0/en
Priority claimed from GBGB9524825.8A external-priority patent/GB9524825D0/en
Application filed by Secr Defence filed Critical Secr Defence
Publication of PT815235E publication Critical patent/PT815235E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT96905956T 1995-03-13 1996-03-13 Vacinas para peste PT815235E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9505059.7A GB9505059D0 (en) 1995-03-13 1995-03-13 Vaccines
GBGB9518946.0A GB9518946D0 (en) 1995-09-15 1995-09-15 Vaccines
GBGB9524825.8A GB9524825D0 (en) 1995-12-05 1995-12-05 Vaccines

Publications (1)

Publication Number Publication Date
PT815235E true PT815235E (pt) 2003-06-30

Family

ID=27267623

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96905956T PT815235E (pt) 1995-03-13 1996-03-13 Vacinas para peste

Country Status (12)

Country Link
US (1) US5985285A (pt)
EP (1) EP0815235B1 (pt)
JP (1) JP3813173B2 (pt)
CN (1) CN1155707C (pt)
AT (1) ATE231184T1 (pt)
AU (1) AU710181B2 (pt)
CA (1) CA2215203C (pt)
DE (1) DE69625802T2 (pt)
DK (1) DK0815235T3 (pt)
ES (1) ES2185762T3 (pt)
PT (1) PT815235E (pt)
WO (1) WO1996028551A1 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3633933B2 (ja) * 1992-07-31 2005-03-30 アカンビス、リサーチ、リミテッド 弱毒化細菌における組換え融合タンパク質の発現
AU5597998A (en) * 1996-12-04 1998-06-29 Heska Corporation Recombinant plague vaccine
US6544522B1 (en) * 1998-12-30 2003-04-08 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US6413768B1 (en) * 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
WO2000056361A2 (en) * 1999-03-24 2000-09-28 The Secretary Of State For Defence Vaccine composition
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB9921275D0 (en) * 1999-09-10 1999-11-10 Secr Defence Recombinant microorganisms
CA2382067A1 (en) * 1999-09-10 2001-03-22 The Secretary Of State For Defence Recombinant microorganisms
WO2001070200A1 (en) * 2000-03-22 2001-09-27 The Secretary Of State For Defence Pharmaceutical composition for administration to mucosal surfaces
US20030219737A1 (en) * 2000-03-28 2003-11-27 Bullard James M. Novel DNA polymerase III holoenzyme delta subunit nucleic acid molecules and proteins
US20040235766A1 (en) * 2001-05-14 2004-11-25 Bullard James M. System for discovery of agents that block yersinia pestis and pseudomonas aeruginosa dna replication
AU2002365223A1 (en) * 2001-10-26 2003-09-02 Id Biomedical Corporation Of Washington Multivalent streptococcal vaccine compositions and methods for use
GB0220257D0 (en) 2002-08-31 2002-10-09 Secr Defence Vaccine
GB0300885D0 (en) * 2003-01-15 2003-02-12 Secr Defence Pharmaceutical composition
US7344718B2 (en) * 2003-01-31 2008-03-18 University Of North Dakota Yersinia species compositions
CA2543080C (en) 2003-10-22 2019-01-08 Id Biomedical Corporation Of Quebec Compositions and methods for activating innate and allergic immunity
WO2005056769A2 (en) * 2003-12-09 2005-06-23 Avant Immunotherapeutics, Inc. Orally-administered live bacterial vaccines for plague
US7875280B2 (en) * 2004-12-02 2011-01-25 The University Of Chicago Methods and compositions involving LcrV proteins
CN101094685B (zh) * 2004-12-16 2016-01-13 韦克福里斯特大学健康科学院 鞭毛蛋白在鼠疫耶尔森氏菌的免疫疗法中的用途
AU2005316265B2 (en) * 2004-12-16 2010-12-23 Wake Forest University Health Sciences Use of flagellin in the immunotherapy of Yersinia pestis
CN101337069B (zh) * 2005-11-25 2012-07-25 中国药品生物制品检定所 复合鼠疫疫苗及其制备方法
GB0525213D0 (en) * 2005-12-12 2006-01-18 Secr Defence Vaccine
US7815911B1 (en) * 2006-10-10 2010-10-19 University Of Kentucky Research Foundation Compositions and methods for treating Yersinia pestis infection
US10174100B1 (en) * 2006-11-06 2019-01-08 Microvax, Llc Multivalent DNA composition for Yersinia pestis
CA2692933C (en) * 2007-07-11 2016-10-18 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
GB0717187D0 (en) * 2007-09-04 2007-10-17 Novartis Ag Compositions comprising yersinia pestis antigens
CN101531710B (zh) * 2009-04-24 2012-05-09 中国疾病预防控制中心传染病预防控制所 rF1抗原及其制备方法与应用
CN101979504A (zh) * 2010-10-26 2011-02-23 中国人民解放军军事医学科学院微生物流行病研究所 鼠疫耶尔森氏菌菌蜕、其制备方法及作为疫苗的应用
CN101985610A (zh) * 2010-10-26 2011-03-16 中国人民解放军军事医学科学院微生物流行病研究所 一种伤寒沙门氏菌菌蜕、制备方法及作为递送系统的应用
WO2012178078A2 (en) 2011-06-22 2012-12-27 University Of North Dakota Use of yscf, truncated yscf and yscf homologs as adjuvants
IN2014DN09618A (pt) * 2012-05-23 2015-07-31 Us Sec Dep Of Health And Human Services
US9328149B2 (en) * 2013-07-12 2016-05-03 The Catholic University Of America Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines
CN106606775A (zh) * 2015-10-27 2017-05-03 格里菲斯大学 脂质体a群链球菌疫苗
RU2671525C2 (ru) * 2015-12-07 2018-11-01 Российская Федерация, от имени которой выступает Министерство обороны Российской Федерации Рекомбинантный вакцинный препарат пролонгированного действия для профилактики чумы у млекопитающих и человека и способ его получения
CN114560932B (zh) * 2022-02-18 2023-09-12 中国人民解放军军事科学院军事医学研究院 一株鼠疫中和抗体及其应用

Also Published As

Publication number Publication date
AU4951196A (en) 1996-10-02
CN1184505A (zh) 1998-06-10
ATE231184T1 (de) 2003-02-15
AU710181B2 (en) 1999-09-16
EP0815235A1 (en) 1998-01-07
CN1155707C (zh) 2004-06-30
US5985285A (en) 1999-11-16
CA2215203A1 (en) 1996-09-19
JP3813173B2 (ja) 2006-08-23
EP0815235B1 (en) 2003-01-15
JPH11501654A (ja) 1999-02-09
DE69625802T2 (de) 2003-11-13
ES2185762T3 (es) 2003-05-01
CA2215203C (en) 2008-12-09
DE69625802D1 (de) 2003-02-20
WO1996028551A1 (en) 1996-09-19
DK0815235T3 (da) 2003-04-22

Similar Documents

Publication Publication Date Title
PT815235E (pt) Vacinas para peste
RU94046232A (ru) Вакцинная композиция, применение композиции, способы лечения, способ приготовления композиции
Rotman et al. IL‐12 eliminates the Th‐2 dependent protective immune response of mice to larval Strongyloides stercoralis
FR2620941B1 (fr) Vaccin contenant des adjuvants et des antigenes tumoraux
ATE456378T1 (de) Behandlung und verhütung von neoplasmatischen und infektiösen erkrankungen mit hitzeschock / stress proteinen
NO20004972L (no) Derivater av pneumokokkale kolinbindende proteiner for vaksiner
FR2697022B1 (fr) Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
KR960700746A (ko) 헬리코박터 피롤리 관련 위십이지장 질환의 치료 방법(treatment of h. pylori associated gastroduodenal disease)
ATE320444T1 (de) Peptide, die die zytotoxische t-lymphozyte antwort gegen hepatitis-b-virus induzieren
DE69031351D1 (de) Zubereitungen und behandlungen von pneumonia in tieren
Wrightsman et al. Paraflagellar rod proteins administered with alum and IL-12 or recombinant adenovirus expressing IL-12 generates antigen-specific responses and protective immunity in mice against Trypanosoma cruzi
HUP9904171A2 (hu) A ragadós száj- és körömfájás vírusok immunogén peptidjei
DE69230855D1 (de) System der bereitstellung eines impfstoffes auf peptidbasis, das sein eigenes adjuvans bildet, und seine herstellung
DE69633233D1 (de) Multivalenter impstoff gegen bovines coronavirus und methode zur behandlung einer infektion mit bovinem coronavirus
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
ES2079851T3 (es) Uso de il-4 para mejorar la respuesta inmunitaria frente a inmunogenos en vacunas.
KR960701208A (ko) 바이러스 단백질에 의해 면역 반응을 자극하는 방법(stimulation of immune response by viral protein)
ES2089371T3 (es) Vacuna contra las enfermedades respiratorias para gatos.
RU2190424C1 (ru) Антигенный состав чумной химической вакцины
DE69833568D1 (de) Isolierte stämme von staphylococcus aureus und daraus hergestellte impfstoffe
BR0110791A (pt) Composição, métodos para induzir uma resposta imune em um indivìduo contra um imunogene, para modular o sistema imune de um indivìduo e para imunizar um indivìduo contra um patógeno, vacina recombinante, e patógeno atenuado vivo
Okuda et al. Cytokine and costimulatory factor-encoding plasmids as adjuvants for DNA vaccination
Cipriano et al. Immunization of salmonids against the fish pathogen, Aeromonas salmonicida
Mikula et al. Stabilization of Salmonella-specific dialyzable leukocyte extracts
Mukerjee et al. Effect of adjuvants on immunization with dengue virus-induced cytotoxic factor